A groundbreaking machine designed to preserve the viability of donated lungs outside the body has the potential to dramatically increase the number of successful lung transplants in England and Wales. Currently, a staggering 77% of available lungs go unused, but with this innovative technology, experts hope to save up to four out of five of these otherwise discarded organs.
A Critical Need for Improved Lung Transplant Rates
The UK consistently ranks poorly in global lung transplantation statistics, with current NHS Blood and Transplant data revealing that 170 patients, including six children, are on the waiting list for new lungs. The average wait time for adults can extend up to two years, and tragically, one in five adults will die within a year of being placed on the transplant list without receiving a suitable organ.
The reasons behind these dismal figures are multifaceted. Many donated lungs are turned down not only due to concerns about their quality but also because of challenges related to staffing and surgical capacity. With a mere 23% of donated lungs being used, the introduction of this new technology could be a game changer.
The XVIVO Machine: How It Works
The XVIVO perfusion system is designed to keep lungs functional while they await transplantation. By warming the donated lungs to body temperature and circulating a fluid that mimics blood plasma, this machine provides a unique opportunity for transplant teams. It not only allows for the monitoring of organ function but also facilitates the treatment of infections, drainage of fluids, and re-expansion of collapsed lung areas.
Draft guidance from the National Institute for Health and Care Excellence (NICE) has now recommended the implementation of this system across the NHS for a four-year evaluation period. This endorsement signifies a major step towards ensuring that all transplant centres, regardless of their size or location, can access and benefit from this vital technology.
Dr Anastasia Chalkidou, the programme director for health technology at NICE, emphasised the importance of this machine, stating, “Every donated lung is a precious gift, and right now too many of them never reach a patient who needs them. This technology has the potential to change that, giving transplant teams the time and information they need to make the most of organs that would otherwise go unused.”
A Call for Broader Support and Research
Jonathan Blades, the head of policy at Asthma + Lung UK, highlighted the urgent need for renewed political and research focus to elevate lung health in the UK. He remarked, “Lung transplant rates in the UK remain lower than in many other developed countries, while respiratory health outcomes remain the worst in Europe.” Blades expressed optimism about the XVIVO system, viewing it as a promising step towards enhancing the quality of life for patients with severe lung conditions.
Prof Andrew Fisher, a consultant transplant physician and member of the British Transplantation Society, echoed these sentiments. He noted the necessity for robust evidence to demonstrate the impact of this device on lung transplantation activities, ensuring that it supports timely access for patients desperately awaiting suitable organs.
Why it Matters
The introduction of the XVIVO perfusion system marks a significant advancement in organ transplantation technology, with the potential to alleviate the pressing issue of wasted lung donations in the UK. By improving the viability of donated organs, this innovation could not only save countless lives but also transform the landscape of respiratory health in the nation. As the healthcare system seeks to bridge the gap between available organs and those in dire need, the implications of this technology extend far beyond the operating theatre, offering hope to families and communities across the country.
